百乐眠治疗冠心病支架术后伴焦虑、抑郁症状的临床研究

The use of Bailemian capsule in the treatment of patients accompanied with anxiety and depression after percutaneous coronary intervention

目的：观察百乐眠治疗冠心病患者植入支架后合并抑郁、焦虑的临床疗效,探讨早期干预治疗对冠心病患者植入支架后合并抑郁、焦虑的重要性。方法：选取我院2012年11月~2014年1月收治的冠心病支架术后合并抑郁、焦虑163例患者随机分为治疗组92例和对照组71例,均接受相同常规治疗,治疗组加用百乐眠,每次4粒每日两次口服,口服2周后观察疗效,重新评定焦虑抑郁量表。结果：与对照组相比,治疗组在临床症状的改善上,难以入睡、失眠、心悸症状明显优于对照组（P〈0.05）。在不同程度抑郁分组中在轻度组治疗效果优于中度组和重度组（P〈0.05）,而在中度组与重度组中差异不明显（P〉0.05）。结论：百乐眠在治疗冠状动脉支架植入术合并抑郁、焦虑过程中有疗效,早期干预治疗尤为重要。

Objective：to evaluate the effect of Bailemian capsule for the patients accompanied with anxiety and depression after PCI. Method： A total of 163 patients were randomly divided into treatment group （n=92）with Bailemian capsule plus routine treatment and control group（n=71 ）with routine treatment for 2 weeks. Clinical efficacy was assessed with the GAD-7 and PHQ-9.Resuh： At the end of the second week, The clinical symptoms in the treated group were significantly better than those in the control group （P〈0.05） and mild group was better than the moderate and severe group （P〈0.05）. There was no significant difference between moderate group and severe group （P〉0.05）. Conclusion： Bailemian capsule has effectiveness in the treatment of patients accompanied with anxiety and depression after percutaneous coronary intervention.